Table 6.

Prognosis-based staging system in Waldenström macroglobulinemia

StageRisk groupPatients, %Criteria5-year OS, %6-1505-year PFS, %6-151
A Low 25 β2M < 3 mg/L + Hb ≥ 120 g/L 87 83  
B Medium 26 β2M < 3 mg/L + Hb < 120 g/L 63 55  
C Medium 28 β2M ≥ 3 mg/L + IgM ≥ 40 g/L 53 33  
D High 21 β2M ≥ 3 mg/L + IgM < 40 g/L 21 12 
StageRisk groupPatients, %Criteria5-year OS, %6-1505-year PFS, %6-151
A Low 25 β2M < 3 mg/L + Hb ≥ 120 g/L 87 83  
B Medium 26 β2M < 3 mg/L + Hb < 120 g/L 63 55  
C Medium 28 β2M ≥ 3 mg/L + IgM ≥ 40 g/L 53 33  
D High 21 β2M ≥ 3 mg/L + IgM < 40 g/L 21 12 

OS indicated overall survival; PFS, progression-free survival; and Hb, hemoglobin.

F6-150

Estimated 5-year OS from initial registration.

F6-151

Estimated 5-year PFS from treatment registration.

View Large